The FDA sign and seal are displayed outside the Food and Drug Administration headquarters building.

Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles

Summit Therapeutics Inc. (NASDAQ:SMMT) is trading at a 52-week low on Monday after the FDA rejected the company’s lead cancer drug application.

On Sunday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating it cannot approve the Biologics License Application (BLA) for ivonescimab in its current form.

Summit seeks approval to combine the novel PD-1 x VEGF bispecific antibody with platinum-containing chemotherapy to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) following prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.

FDA Cites Overall Survival Data

Regulators determined Summit failed to establish substantial evidence of effectiveness without a statistically significant overall survival (OS) improvement.

The FDA noted progression-free survival (PFS) gains alone do not support a positive benefit-risk profile without statistically significant OS improvement.

The company noted that no FDA-approved regimens currently demonstrate a statistically significant OS benefit in this setting. While ivonescimab plus chemotherapy showed a positive OS trend in the primary analysis, it missed statistical significance.

However, a post-hoc analysis with longer-term Western patient follow-up showed a consistent OS benefit across regions, yielding a 0.76 hazard ratio across the full population, Asian patients, and Western patients.

HARMONi Trial And Safety Results

Data from the HARMONi Phase 3 trial supported the BLA. The study evaluated ivonescimab plus chemotherapy against placebo plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC patients previously given a third-generation EGFR TKI.

HARMONi met its PFS primary endpoint, becoming the first global Phase 3 immunotherapy-based regimen study demonstrating a statistically significant PFS improvement in this setting, which more mature Western patient data supported.

The combination showed an acceptable, manageable safety profile consistent with prior studies, with no new safety signals and comparable discontinuation and death rates across arms.

Global Regulatory Status

No regulatory authority in Summit’s license territories, including the U.S. and Europe, has approved ivonescimab, and the U.S. lacks approved PD-1 x VEGF bispecific antibodies.

China initially approved ivonescimab in May 2024.

SMMT Price Action: Summit Therapeutics shares were down 17.31% at $11.70 during premarket trading on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs